Table 1.

Summary of patient characteristics at each study

Study	Bolus injection study	Bolus injection + infusion study	Bolus injection study	Bolus injection + infusion study	Long term infusion study
	Healthy volunteers	Healthy volunteers	Patients	Patients	Patients
n	5	6	28	46	20
Number of observation	105	175	159	79	100
Dose	6, 12, 18, 24 mg	Bolus: 12 mg Infusion: 6, 9, 12 mg h−1 for 235 min	4, 8, 12, 18 mg	Bolus: 200 µg kg−1Infusion: 50–200 µg kg−1 for 24 h	Bolus: 200 µg kg−1Infusion: 50–200 µg kg−1 for 48 h
Demographics
Age (years)	33.0 ± 7.7	41.2 ± 5.9	62.8 ± 12.8	65.1 ± 11.5	70.8 ± 8.4
Weight (kg)	62.6 ± 8.6	63.6 ± 6.4	58.6 ± 11.3	60.3 ± 10.7	61.8 ± 10.2
Sex
Male	5	6	21	30	14
Female	0	0	7	16	6
NYHA classification
II	–	–	3	10	4
III	–	–	10	12	6
IV	–	–	15	24	10
PAWP at predose (mmHg)	–	–	25.9 ± 6.4	26.9 ± 6.3	27.2 ± 7.4
CI at predose (l min−1 m−2)	–	–	2.52 ± 0.70	2.47 ± 0.88	2.22 ± 0.43
Cause
Ischaemic heart disease	–	–	11	16	6
Valvular heart disease	–	–	6	14	2
Hypertensive heart disease	–	–	4	7	2
Dilaed cardiomyopathy	–	–	7	9	6

Data are shown as mean ± SD.